Events, By Category and Date:
» Go to news mainPermissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
Posted by nte on
February 24, 2023
in
In Print
Sud A, McGee M, Mintzes B, Herder M. Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. Int J Drug Policy. 2022 Jul;105:103749. doi: 10.1016/j.drugpo.2022.103749. Epub 2022 May 26. PMID: 35643048.
Recent News
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize